Because targeting the RAS-MEK-ERK and PI3K-PTEN-AKT-mTOR signaling pathways might logically affect the growth of nf1/pten-mutant melanomas, we first transplanted these melanoma cells into 3-week-old rag2−/− zebrafish and treated the recipients with MEK (trametinib or cobimetinb) or pan-PI3K (buparlisib or apitolisib) inhibitors. The gene discussed is AKT1; the disease is melanoma.